McKesson to Acquire Precision Medicine Group, Expanding Specialty Capabilities
MCK sits 30% above its 52-week low of $673.38.
Summary
McKesson has signed an agreement to acquire Precision Medicine Group, LLC for about $2.25 billion, expanding its specialty and precision medicine capabilities. The deal follows a strong fiscal Q1 and a $2.25B term loan secured in June, suggesting strategic deployment of capital. The acquisition aligns with McKesson's focus on high-growth specialty segments and will enhance clinical research and commercialization services. The transaction is subject to customary closing conditions and regulatory approvals.
At the time of this announcement, MCK was trading at $873.29 on NYSE in the Trade & Services sector, with a market capitalization of approximately $101.9B. The 52-week trading range was $673.38 to $999.00. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.